Distinguished University Health Professor Emeritus, University of South Florida College of Medicine

Psychiatry

Dr. David V. Sheehan is an expert in the field of Psychiatry. He received 1 awards: "Super Doctor". David V. Sheehan is a published doctor as well. He has 101 publications published. The latest was: A diagnostic aid for detecting (DSM-IV) mental disorders in primary care.

Publications

---

• Content validity of the Sheehan Irritability Scale in patients with major depressive disorder.
• Longitudinal Modeling The Effect Of Lisdexamfetamine Dimesylate And Changes In Binge Eating Frequency On Disability In Patients With Binge Eating Disorder.
• Comparative Validation of the S-STS, the ISST-Plus, and the C-SSRS for Assessing the Suicidal Thinking and Behavior FDA 2012 Suicidality Categories.
• Simple Measures of Hopelessness and Impulsivity are Associated with Acute Suicidal Ideation and Attempts in Patients in Psychiatric Crisis.
• Current Assessment and Classification of Suicidal Phenomena using the FDA 2012 Draft Guidance Document on Suicide Assessment: A Critical Review.
• The Columbia-Suicide Severity Rating Scale (C-SSRS): Has the "Gold Standard" Become a Liability?
• Status Update on the Sheehan-Suicidality Tracking Scale (S-STS) 2014.
• The complexity of assessing overall severity of suicidality: a case study.
• Do the Five Combinations of Suicidal Ideation in the FDA 2012 Draft Guidance Document and the C-SSRS Adequately Cover All Suicidal Ideation Combinations in Practice? A...
• Is a count of suicidal ideation and behavior events useful in assessing global severity of suicidality? A case study.
• Is There Value in Asking the Question "Do you think you would be better off dead?" in Assessing Suicidality? A Case Study.
• How the Timing of a Patient's Self-ratings of Suicidality and the Relationship to the Recipient Affect Patient Responses: A Case Study.
• Linguistic Validation of the Pediatric Versions of the Sheehan Suicidality Tracking Scale (S-STS).
• A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder.
• Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): Data from a randomized-...
• Relationship between major depressive disorder and associated painful physical symptoms: analysis of data from two pooled placebo-controlled, randomized studies of dul...
• Characteristics of responders and non-responders to risperidone monotherapy or placebo in co-occurring bipolar disorder and anxiety disorder.
• Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind,...
• Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient.
• Humanistic and economic burden of generalized anxiety disorder in North America and Europe.
• Patients with obsessive-compulsive disorder vs depression have comparable health care costs: A retrospective claims analysis of Florida Medicaid enrollees.
• Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine.
• The use of research measures in adult clinical practice.
• Antidepressant use in geriatric populations: the burden of side effects and interactions and their impact on adherence and costs.
• Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem exten...
• Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a brief report.
• Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement.
• Expenditures associated with dose titration at initiation of therapy in patients with major depressive disorder: a retrospective analysis of a large managed care claim...
• Reliability and validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID).
• Benzodiazepines risk, abuse, and dependence: a tsunami in a tea cup.
• Adequacy of pharmacotherapy among medicaid-enrolled patients newly diagnosed with obsessive-compulsive disorder.
• Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study.
• The Efficacy and Tolerability of Once-daily Controlled-release Trazodone for Depressed Mood, Anxiety, Insomnia, and Suicidality in Major Depressive Disorder.
• Sheehan Suicidality Tracking Scale (Sheehan-STS): Preliminary Results from a Multicenter Clinical Trial in Generalized Anxiety Disorder.
• Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine.
• Current approaches to the pharmacologic treatment of anxiety disorders.
• The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorder.
• An open-label study of tiagabine in panic disorder.
• Generic Conversion of the SSRI Market and the Impact on Branded Products.
• Differences in total medical costs across the SSRIs for the treatment of depression and anxiety.
• Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy.
• Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine.
• Depression: underdiagnosed, undertreated, underappreciated.
• Improved tolerability and increased length of therapy.
• Paroxetine treatment of generalized anxiety disorder.
• The importance of adequate length of antidepressant therapy.
• Establishing the real cost of depression.
• Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine.
• Impact of formulary restrictions on the cost-effectiveness of antidepressant treatment.
• The management of panic disorder.
• Generalized anxiety disorder: raising the expectations of treatment.
• The Ontario Mother and Infant Survey: breastfeeding outcomes.
• Unusual complication after left-lobe liver biopsy for diffuse liver disease: severe bleeding from the superior epigastric artery.
• Panic disorder in genotypic HLA identical sibling pairs.
• A combination drug treatment for acute common migraine.
• Mental disorders and disability among patients in a primary care group practice.
• Relations among stressors, strains, and substance use among resident physicians.
• Differentiating panic disorders from dental anxiety.
• A pilot study of medical student 'abuse'. Student perceptions of mistreatment and misconduct in medical school.
• Costs of postpartum care: examining associations from the Ontario mother and infant survey.
• The prevalence of mitral valve prolapse in patients with panic disorders.
• Dental anxiety--the development of a measurement model.
• Voriconazole susceptibilities of dermatophyte isolates obtained from a worldwide tinea capitis clinical trial.
• A case of bupropion-induced seizure.
• DSM-IH-R Psychotic Disorders: procedural validity of the Mini International Neuropsychiatric Interview (MINI). Concordance and causes for discordance with the CIDI.
• Behavioral consequences of job-related stress among resident physicians: the mediating role of psychological strain.
• Current concepts in psychiatry. Panic attacks and phobias.
• Monoamine oxidase inhibitors: prescription and patient management.
• Panic anxiety: a new biological model.
• Medical evaluation of panic attacks.
• Multivariate analysis of changes in panic frequency counts.
• Panic attacks and the dexamethasone suppression test.
• Age of onset of phobic disorders: a reevaluation.
• Diagnostic classification of anxiety and phobic disorders.
• A diagnostic aid for detecting (DSM-IV) mental disorders in primary care.
• Substance use by fourth-year students at 13 U.S. medical schools.
• False positive results: a challenge for psychiatric screening in primary care.
• Patterns of substance use in the medical profession.
• Resident physician substance use, by specialty.
• Cocaine use by senior medical students.
• Immunological response to stress in agoraphobia and panic attacks.
• Occurrence of the Cys311 DRD2 variant in a pedigree multiply affected with panic disorder.
• Panic anxiety: diagnosis, etiology, and treatment.
• Neuroendocrine correlates of lactate-induced anxiety and their response to chronic alprazolam therapy.
• Differentiating anxiety-panic disorders from psychologic dental anxiety.
• Tricyclic antidepressants in the treatment of panic and anxiety disorders.
• The diagnosis and drug treatment of anxiety disorders.
• Vasopressin response to lactate infusion in normals and patients with panic disorder.
• Suicidal ideation in primary care.
• Evaluation of screens for mental disorders in primary care: methodological issues.
• Diagnostic errors of primary care screens for depression and panic disorder.
• Have drug companies hyped social anxiety disorder to increase sales. No: Efforts to relieve human suffering deserve rewards.
• Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms.
• Lactate infusion in anxiety research: its evolution and practice.
• Generalized anxiety disorder: comorbidity, comparative biology and treatment.
• The classification of anxiety and hysterical states. Part I. Historical review and empirical delineation.
• The classification of anxiety and hysterical states. Part II. Toward a more heuristic classification.
• Mitral valve prolapse and panic disorder.
• Resident physician substance use in the United States.
• Snorting benzodiazepines.

Schools

---

• University College of Cork National University of Ireland

• Stamford Hospital

• Boston City Hospital

• Massachusetts General Hospital

• Menninger School Psychology

Doctors Specialties

---

• Psychiatry

Accepted Insurances

---

• Amerigroup (Wellpoint)
• Blue Cross Blue Shield
• Great West Healthcare-Cigna PPO
• Choice Care PPO
• Medicaid
• United Healthcare

Awards

---

• Super Doctor

Education

---

• Massachusetts General Hospital
• University College of Dublin National Univ SOM

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Kimberly E. Hartney, MD This Doctor is OpenDoctor Recommended.
	Dr. Alfonso H. Saa, MD This Doctor is OpenDoctor Recommended.
	Dr. Deborah Roth, DO
	Dr. Dan R. Richards, MD This Doctor is OpenDoctor Recommended.
	Dr. Mildred C. Barnett, MD This Doctor is OpenDoctor Recommended.
	Dr. Julia L. Winston, MD This Doctor is OpenDoctor Recommended.
	Dr. Rosario B. Hidalgo, MD This Doctor is OpenDoctor Recommended.
	Dr. Luke R. Michels, MD
	Dr. Arlene E. Nunez, MD This Doctor is OpenDoctor Recommended.
	Dr. Hailing Zhang, MD This Doctor is OpenDoctor Recommended.
	Dr. Morgan W. Nesmith, MD This Doctor is OpenDoctor Recommended.
	Balebail A. Raj, MB This Doctor is OpenDoctor Recommended.
	Dr. Mary E. Turner, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog